Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy T Batchelor

Showing results (151-160 of 268) with videos related to

Pageof 27
Sort By:
Nature Medicine|August 20, 2013
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapyKyrre E Emblem, Kim Mouridsen, Atle Bjornerud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology GuidelineErik P Sulman, Nofisat Ismaila, Terri S Armstrong, et al.
Neuro-Oncology|October 28, 2020
Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtypeJian Teng, Seyedali Hejazi, Lotte Hiddingh, et al.
Journal of Neuro-Oncology|December 16, 2014
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort studyMilan G Chheda, Patrick Y Wen, Fred H Hochberg, et al.
Neuro-Oncology|July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patientsKourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Neuro-Oncology|November 4, 2017
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtypeJian Teng, Seyedali Hejazi, Lotte Hiddingh, et al.
Journal of Neuro-Oncology|July 24, 2012
Prospective, high-throughput molecular profiling of human gliomasAndrew S Chi, Tracy T Batchelor, Dora Dias-Santagata, et al.
Cancer Research|June 25, 2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patientsA Gregory Sorensen, Tracy T Batchelor, Wei-Ting Zhang, et al.
German Medical Science : GMS E-Journal|June 24, 2011
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysisKatrin Patrij, Marcel Reiser, Luise Wätzel, et al.
Cancer Research|June 20, 2017
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated CytotoxicityKensuke Tateishi, Fumi Higuchi, Julie J Miller, et al.
Pageof 27

Showing results (151-160 of 268) with videos related to

Sort By:
Pageof 27
Nature Medicine|August 20, 2013
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapyKyrre E Emblem, Kim Mouridsen, Atle Bjornerud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology GuidelineErik P Sulman, Nofisat Ismaila, Terri S Armstrong, et al.
Neuro-Oncology|October 28, 2020
Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtypeJian Teng, Seyedali Hejazi, Lotte Hiddingh, et al.
Journal of Neuro-Oncology|December 16, 2014
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort studyMilan G Chheda, Patrick Y Wen, Fred H Hochberg, et al.
Neuro-Oncology|July 7, 2016
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patientsKourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, et al.
Neuro-Oncology|November 4, 2017
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtypeJian Teng, Seyedali Hejazi, Lotte Hiddingh, et al.
Journal of Neuro-Oncology|July 24, 2012
Prospective, high-throughput molecular profiling of human gliomasAndrew S Chi, Tracy T Batchelor, Dora Dias-Santagata, et al.
Cancer Research|June 25, 2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patientsA Gregory Sorensen, Tracy T Batchelor, Wei-Ting Zhang, et al.
German Medical Science : GMS E-Journal|June 24, 2011
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysisKatrin Patrij, Marcel Reiser, Luise Wätzel, et al.
Cancer Research|June 20, 2017
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in <i>IDH1</i>-Mutant Cancers and Potentiates NAD<sup>+</sup> Depletion-Mediated CytotoxicityKensuke Tateishi, Fumi Higuchi, Julie J Miller, et al.
Pageof 27